NYT: The company announced it would buy the biotechnology company for $1.75 billion in cash.
NYT: The company announced it would buy the biotechnology company for $1.75 billion in cash.
Alios is developing a promising orally administered treatment for respiratory syncytial virus, known as RSV. It is currently in Phase 2 studies.
“We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy,” said William N. Hait, the head of research and development at Janssen Pharmaceutical Companies, a division of Johnson & Johnson. The compound Alios is developing “complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.”
Read more here.
